trending Market Intelligence /marketintelligence/en/news-insights/trending/b4nnKgMBAn29ZBZbnS0HgQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Cumberland's application for arthritis, psoriasis drug accepted by US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Cumberland's application for arthritis, psoriasis drug accepted by US FDA

Cumberland Pharmaceuticals Inc. said the U.S. Food and Drug Administration will decide by November whether to approve its drug product line for treating arthritis and psoriasis.

The Nashville, Tenn.-based specialty pharmaceutical company said in an SEC filing that the U.S. regulator accepted for review the new drug application for its methotrexate product line to treat adults and children with arthritis and adults with psoriasis.

Arthritis is an inflammation or degeneration of one or more joints in the body, while psoriasis is a chronic skin condition caused by an overactive immune system and characterized by patches of abnormal skin.

Cumberland had submitted the application in November 2018 and paid $1.3 million to the FDA as application fee.

In 2016, Cumberland had agreed to acquire the exclusive U.S. rights to Nordic Group BV's injectable methotrexate product line used for treating active rheumatoid arthritis, juvenile idiopathic arthritis, severe psoriatic arthritis and severe disabling psoriasis.